Abeona Therapeutics
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Ohio, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
6555 Carnegie Ave Fl 4, Cleveland, Ohio,...Phone Number
(646) 813-4701Website
www.abeonatherapeutics.comRevenue
$14.5 MillionStock Symbol
ABEOIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Abeona Therapeutics
Abeona Therapeutics Inc. is a publicly traded, commercial-stage biopharmaceutical company headquartered in Cleveland, Ohio, and listed on the NASDAQ under the ticker ABEO. Formerly known as PlasmaTech Biopharmaceuticals, the company develops and commercializes cell and gene therapies for serious rare diseases. Its lead product, ZEVASKYN (prademagene zamikeracel), is an FDA-approved autologous, cell-based gene therapy for recessive dystrophic epidermolysis bullosa (RDEB). Abeona also maintains a pipeline of AAV-based gene therapies targeting ophthalmic diseases, supported by its proprietary AIM Vector Platform of next-generation AAV capsids. The company operates a fully integrated cGMP manufacturing facility in Cleveland, Ohio.Explore more
Abeona Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Abeona Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Abeona Therapeutics has new funding data
Website visits: Recent activity has been detected on your website
Check if Abeona Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Click to see if Abeona Therapeutics had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Abeona Therapeutics launches new products
Check out if Abeona Therapeutics is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Abeona Therapeutics
Abeona Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Abeona Therapeutics recently announced quarterly report
Recommended Actions
Reach out to Masked Content who joined Abeona Therapeutics as Masked Content
Find more new buyers
Compare Similar Companies to Abeona Therapeutics
Compare insights from companies similar to Abeona Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Abeona Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Abeona Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Abeona Therapeutics.
Abeona Therapeutics financials insights
Gather financial insights about Abeona Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Other Financing Round
$3.6M
2015
Share Placement
$8.5M
2017
Grant
$13.8M
Share Placement
$92M
2019
Stock Offering
$103.5M
2020
Debt
$1M
2022
Other Financing Round
$35M
2023
Share Placement
$25M
Abeona Therapeutics Tech Stack
A closer look at the technologies used by Abeona Therapeutics
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Person-Based
Medical Research
Project
Medical Administration
Abeona Therapeutics News & Media
CMS Grants New Technology Add-On Payment (NTAP) Status for ZEVASKYN®
NTAP Designation Expected to Support Medicare Patient Access, Treatment Center Economics and Commercial Adoption NTAP Designation Expected to Support Medicare Patient Access, Treatment Center Economics and Commercial AdoptionAbeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CLEVELAND, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Abeona Therapeutics Inc. (NASDAQ: ABEO)
NEW YORK, July 27, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Abeona Therapeutics Inc. (NASDAQ: ABEO) on behalf of the company's shareholders. The investigation seeks to determine whether Abeona Therapeutics's directors breached their fiduciary duties...Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®
CLEVELAND, July 21, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases, today announced the activation of Cincinnati Children’s as the seventh Qualified Treatment Center (QTC) for the administration of ZEVASKYN® (prademagene zamikeracel), the first and only autologous gene-modified cellular sheets for the treatment of wounds in patients with recessive dystrophic epidermolysis bullo
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Frequently Asked Questions Regarding Abeona Therapeutics
Sign Up For FreeTo access detailed company insights
Abeona Therapeutics Inc. is a publicly traded, commercial-stage biopharmaceutical company headquartered in Cleveland, Ohio, and listed on the NASDAQ under the ticker ABEO. Formerly known as PlasmaTech Biopharmaceuticals, the company develops and commercializes cell and gene therapies for serious rare diseases. Its lead product, ZEVASKYN (prademagen... Read More
